Related Experiment Video

Updated: Oct 7, 2025

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.9K

Post-translational modifications of CDK5 and their biological roles in cancer

Gui-Bin Gao1, Yue Sun1, Run-Dong Fang1

  • 1MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.

Molecular Biomedicine
|January 10, 2022
PubMed

Insights

Post-translational modifications (PTMs) of Cyclin-dependent kinase 5 (CDK5) regulate cancer. Targeting these CDK5 PTMs shows promise for new cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Cyclin-dependent kinase 5 (CDK5) plays a critical role in cancer progression.
  • Aberrant CDK5 expression is linked to key cancer hallmarks like proliferation and angiogenesis.
  • Post-translational modifications (PTMs) are emerging as crucial regulators of CDK5 activity in cancer.

Purpose of the Study:

  • To review the role of PTMs on CDK5 signaling in malignant tumors.
  • To discuss the mechanisms and biological significance of CDK5 PTMs in cancer.
  • To explore therapeutic strategies targeting CDK5 PTMs for cancer treatment.

Main Methods:

  • Literature review of studies on CDK5 PTMs and their role in cancer.
  • Analysis of signaling cascades regulated by CDK5 PTMs.
  • Evaluation of preclinical data on therapeutic interventions targeting CDK5 PTMs.

Main Results:

  • Several PTMs, including S-nitrosylation, sumoylation, and acetylation, act as molecular switches for CDK5 kinase activity.
  • Many CDK5 PTMs and their specific roles in cancer remain uncharacterized.
  • Targeting CDK5 PTMs with chemical compounds, inhibitors, or peptides demonstrates significant antitumor effects in preclinical studies.

Conclusions:

  • PTMs critically modulate CDK5 function and its involvement in cancer development.
  • Targeting CDK5 PTMs represents a promising avenue for novel cancer therapeutics.
  • Further research and clinical translation of CDK5 PTM-targeting strategies are warranted.
Keywords:
CDK5CancerPosttranslational modifications

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

327
Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk113:15

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Published on: February 25, 2016

12.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.4K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
7.7K